R3767-ONC-22122: A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab In Participants with Unresectable or Metastatic Melanoma
- Title
- A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab In Participants with Unresectable or Metastatic Melanoma
- Principal Investigator
- Kolodney, Joanna
- Phase
- III
- Age Group
- Adult
- Applicable Disease Sites
- Melanoma and Other Skin Cancers
- Participating Institutions
- Mary Babb Randolph Cancer Center
- Contacts
- Meg Zafiris
- Research Specialist
- Email: margaret.zafiris@hsc.wvu.edu